1 Rapid proteotyping reveals cancer biology and drug response determinants in the NCI-

- 2 **60 cells**
- 3
- 4 Tiannan Guo^{1,19}*[#], Augustin Luna^{2,3}*, Vinodh N Rajapakse⁴*, Ching Chiek Koh¹*†,
- 5 Zhicheng Wu¹⁹, Michael P Menden^{5,21}, Yongran Cheng¹⁹, Laurence Calzone⁶, Loredana
- 6 Martignetti ⁶, Alessandro Ori ⁷, Murat Iskar ⁸¹, Ludovic Gillet ¹, Qing Zhong ^{9,20}, Sudhir
- 7 Varma¹⁰, Uwe Schmitt¹¹, Peng Qiu¹², Yaoting Sun¹⁹, Yi Zhu^{1,19}, Peter J Wild⁹, Mathew J
- 8 Garnett ¹³, Peer Bork ^{8, 14,15,16}, Martin Beck ^{8, 17}, Julio Saez-Rodriguez ⁵, William C. Reinhold
- 9⁴, Chris Sander ^{2,3}, Yves Pommier ⁴[#], Ruedi Aebersold ^{1, 18}[#]
- 10
- 11 * Equal contribution
- 12 # correspondence
- 13

14 Affiliations

- 15 1, Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Switzerland
- 16 2, cBio Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer
- 17 Institute, Boston, MA 02115, USA
- 18 3, Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
- 19 4, Developmental Therapeutics Branch, Center for Cancer Research, National Cancer
- 20 Institute, National Institutes of Health, Bethesda, MD 20892, United States
- 21 5, RWTH Aachen University, Faculty of Medicine, Joint Research Centre for Computational
- 22 Biomedicine (JRC-COMBINE), Germany
- 6, Institut Curie, PSL Research University, INSERM, U900, Mines Paris Tech, F-75005,
- 24 Paris, France.
- 25 7, Leibniz Institute on Aging, Fritz Lipmann Institute (FLI), Beutenbergstrasse 11, 07745
- 26 Jena, Germany
- 8, Structural and Computational Biology Unit, European Molecular Biology Laboratory,
- 28 69117 Heidelberg, Germany
- 29 9, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
- 30 10, HiThru Analytics, Laurel, MD 20707, USA
- 31 11, Scientific IT Services, ETH Zurich, Switzerland
- 32 12, Department of Biomedical Engineering, Georgia Institute of Technology and Emory
- 33 University, 313 Ferst Dr., Atlanta, GA 30332, US
- 13, Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK

- 14, Molecular Medicine Partnership Unit, University of Heidelberg and European Molecular
- 36 Biology Laboratory, 69120 Heidelberg, Germany
- 37 15, Max Delbrück Centre for Molecular Medicine, 13125 Berlin, Germany
- 16, Department of Bioinformatics, Biocenter, University of Würzburg, 97074 Würzburg,
- 39 Germany
- 40 17, Cell Biology and Biophysics Unit, European Molecular Biology Laboratory, 69117
- 41 Heidelberg, Germany
- 42 18, Faculty of Science, University of Zurich, Zurich, Switzerland
- 43 19, Westlake Institute for Advanced Study, Westlake University, Hangzhou, Zhejiang, P. R.
- 44 China
- 45 20, Cancer Data Science Group, Children's Medical Research Institute, University of Sydney,
- 46 Sydney, New South Wales, Australia.
- 47 21, Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK
- 48

49 [†], current address: Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge

- 50 CB10 1SA, UK
- 51 l, current address: Division of Molecular Genetics, German Cancer Research Center (DKFZ),
- 52 Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
- 53

54 Summary

55

56 We describe the rapid and reproducible acquisition of quantitative proteome maps for the

- 57 NCI-60 cancer cell lines and their use to reveal cancer biology and drug response
- determinants. Proteome datasets for the 60 cell lines were acquired in duplicate within 30
- 59 working days using pressure cycling technology and SWATH mass spectrometry. We
- 60 consistently quantified 3,171 proteotypic proteins annotated in the SwissProt database across
- all cell lines, generating a data matrix with 0.1% missing values, allowing analyses of protein
- 62 complexes and pathway activities across all the cancer cells. Systematic and integrative
- analysis of the genetic variation, mRNA expression and proteomic data of the NCI-60 cancer
- 64 cell lines uncovered complementarity between different types of molecular data in the
- prediction of the response to 240 drugs. We additionally identified novel proteomic drug
- response determinants for clinically relevant chemotherapeutic and targeted therapies. We
- 67 anticipate that this study represents a significant advance toward the translational application
- of proteotypes, which reveal biological insights that are easily missed in the absence of
- 69 proteomic data.

70 Introduction

71

To date, mainly owing to the maturity and availability of high throughput DNA- and 72 RNA- based techniques, forays into the molecular landscape of diseases, in particular cancers, 73 have primarily focused on genomics and transcriptomics ¹⁻³. Protein-level measurements, 74 although showing great potential for providing the granularity and details necessary for 75 personalized therapeutic decisions, are underutilized due to technical hurdles. Advances in 76 77 data-dependent acquisition (DDA) mass spectrometry (MS) have permitted quantitative proteomic profiling of about 100 tumor samples using multi-dimensional fractionated MS 78 analyses of each sample ⁴⁻⁶, demonstrating the added value of protein measurement in 79 classifying tumor samples. Nevertheless, such DDA workflows suffer from relatively lower 80 81 sample-throughput, relatively higher sample consumption and technical complexity, precluding their routine use in clinically relevant applications (e.g. drug response prediction) 82 on the speed and scale achieved by genomic and transcriptomic approaches ^{2,3}. 83 84

85 To achieve reproducible and high throughput proteomic profiling, we have developed a workflow ^{7,8} integrating pressure cycling technology (PCT), an emerging sample 86 87 preparation method that accelerates and standardizes sample preparation for proteomic profiling⁹, together with SWATH-MS, an MS-based proteomic technique that consists of 88 89 data independent acquisition (DIA) and a targeted data analysis strategy with unique advantages over other MS-based proteomic methods ^{10, 11}. With this technique all MS-90 measurable peptides of a sample are fragmented and recorded in a recursive fashion, thus 91 92 generating digital proteome maps that can be used to reproducibly detect and quantify proteins across high numbers of samples without the need of isotope labeling. The PCT-93 SWATH technique thus significantly increases the sample throughput and data reproducibility 94 providing excellent quantitative accuracy, and also reduces sample consumption to ca. 1 95 microgram of total peptide mass per sample ^{7, 8}. 96

97

In this study, we describe the acquisition of proteome maps of the NCI-60 cell lines in duplicate by PCT-SWATH. The 120 proteome maps were acquired within 30 working days on a single instrument and each sample consumed ca. 1 microgram of total peptide mass. We consistently quantified 3,171 SwissProt proteotypic proteins across all cell lines, generating a data matrix (120 proteomes vs. 3171 proteins) with 0.1% missing values. Raw signals of each peptide and protein in each sample were curated with an expert system. The NCI-60 human

cancer cell line panel contains 60 lines from 9 different tissue types ¹². The NCI-60 have been 104 molecularly and pharmacologically characterized with unparalleled depth and coverage, 105 106 offering a prime in vitro model to further our understanding of cancer biology and cellular responses to anti-cancer agents ^{12, 13}. Discoveries enabled by the NCI-60 in recent years 107 include the development of the FDA approved drugs oxaliplatin for the treatment of colon 108 cancers ¹⁴, eribulin for metastatic breast cancers ¹², bortezomib for the treatment of multiple 109 myeloma¹⁵, and rhomidepsin for cutaneous T-cell lymphomas¹⁶. The sensitivity of the NCI-110 60 has been measured for over 100,000 synthetic or natural compounds derived from a wide 111 range of academic and industrial sources ¹², constructing the most comprehensive resource for 112 cancer pharmacological research. The proteomic data complement the existing NCI-60 113 114 molecular landscapes, allowing systematic investigation of the complementarity among genomics, transcriptomics and proteomics in a number of applications. 115 116

The proteome of the NCI-60 cells has been analyzed previously by data dependent 117 analysis (DDA), a commonly used discovery mass spectrometry technique ¹⁷. Whereas the 118 study reported the cumulative identification of 10,350 IPI proteins from about 1,000 119 120 fractionated and kinase-enriched sample runs, only 492 proteins were quantified across the NCI-60 cell lines without missing value. The present study thus extends the number of 121 proteins consistently quantified in duplicates analyses to 3,171, a ca. six-fold increase. The 122 high quality proteomic data were used for pharmacoproteomic analysis of the response of the 123 cell panel to 240 anti-cancer drugs, resulting in the identification of novel proteomic drug 124 response determinants for clinically relevant chemotherapeutic and targeted therapies. 125

126 **Results**

127

128 Acquisition of the NCI-60 proteome maps

129

We applied the PCT-SWATH workflow ⁷ to generate quantitative proteome maps of 130 the NCI-60 cell lines in technical replicates, resulting in the generation of 120 SWATH maps 131 with high reproducibility at the raw data level (Supplementary Fig. 1). The PCT-assisted 132 sample preparation took about 18 working days and the SWATH-MS data acquisition 133 134 consumed about 12 working days. Thus, the entire process, from sample preparation to data acquisition, was accomplished within 30 working days. This constitutes an unprecedented 135 sample-throughput compared to other cancer proteomic workflows of similar scale ^{4-6, 17}. This 136 is the result of the elimination of multidimensional fractionation and the consequential sample 137 138 processing of each sample through using one barocycler to one mass spectrometer in which a single file per sample was acquired (Supplementary Fig. 1, Supplementary Table 1). 139 140

SWATH proteome maps contain fragment ion chromatograms from all MS-measurable 141 142 peptides, albeit in a highly convoluted form. To interpret the SWATH maps, we built a human cancer cell line spectral library containing 86,209 proteotypic peptides, *i.e.* peptides that 143 uniquely identify a specific protein, from 8,056 SwissProt proteins (Supplementary Table 144 1). Using this library and the OpenSWATH software ¹¹, we identified 6,556 protein groups, 145 covering 81% of the library (Supplementary Fig. 2). To avoid ambiguity of peptide/protein 146 quantification, we limited our analyses to canonical and proteotypic peptides and proteins by 147 excluding protein isoforms, un-reviewed protein sequences, peptide/protein sequence variants 148 149 and protein groups that could not be deconvoluted.

150

We evaluated the technical variation of each measurement through manual inspection of the OpenSWATH results based on the replicated measurement for each cell line and observed in substantial technical variation. This is probably due to the fact that cell typespecific interfering signals leads to invalid SWATH assays, and the presence of irregular liquid chromatography (LC) and MS behavior of certain peptides in the highly variable proteomic context of the NCI-60 cells. These phenomena have also been observed previously in selected reaction monitoring (SRM)-based targeted proteomics studies ¹⁸.

To obtain high accuracy quantitative data for the cell lines, we further developed an 159 160 expert system, *i.e.* DIA-expert (see Methods), to refine the peptide identification and quantification provided by automated analysis tools like OpenSWATH (Fig. 1A). We thus 161 162 excluded proteins and peptides that were not reproducibly quantified in technical replicates and focused our analyses on a shorter list of 22,554 proteotypic peptides from 3,171 proteins, 163 with 8% missing values at the peptide level and 0.1% missing values at the protein level 164 across all MS runs (Supplementary Table 1). On average, 7 peptide precursors and 6 unique 165 peptide sequences were identified for each protein (Fig. 1B). Several proteins were identified 166 167 with more than 200 peptides (Fig. 1C). The proteins excluded by DIA-expert may not be incorrect identifications, but rather proteins that could not achieve reproducible quantification 168 by the existing algorithm across all cell lines due to either technical issues, for instance the 169 170 signal-to-noise ratio, or biological issues such as post-translational modifications or splicing 171 variants. Improved computational methods will likely rescue some of them in the future. 172 173 Most peptides for the 3.171 proteins were consistently quantified in all cell lines at both MS1 and MS2 levels. Two representative peptides are shown in Fig. 1A. The coefficient 174 175 of determination (\mathbf{R}^2) between technical replicates, for overall expression of peptides (**Fig.** 176 1D) and proteins (Fig. 1E), were 0.974 and 0.978, respectively, with a dynamic range over 5 orders of magnitude (Fig. 1F). We provide the raw MS signals for each quantitative value in 177 **Supplementary File 1**, allowing visual inspection of the MS signal for every peptide in each 178 sample. When we set the minimal number of peptides identified per protein to 2, 3 or 4, 179 respectively, fewer proteins (2200, 1741, 1428 proteins respectively) were quantified, 180

181 however, the quantitative accuracy did not substantially improve, indicating that protein

182 quantification by a single, reliably identified proteotypic peptide is similarly accurate as

183 quantification by multiple proteotypic peptides (**Supplementary Figure 3**).






Figure 1. Acquisition of NCI-60 proteotype. (A) Representative peptide signals as curated and visualized by
the DIA-expert software. (B) The cumulative number of peptides and peptide precursors identified for each
protein. (C) The distribution of peptide precursors and peptides per protein. The overall Pearson correlation
between technical replicates at the peptide level (D) and the protein level (E). Here, the log10 transformed
intensity of each peptide/protein in each cell line technical replicate is plotted in the heatmap. (F) Dynamic range
of the MS signals for 22,968 proteotypic peptides.

192

193 Characterization of the NCI-60 quantitative proteomes


194

The landscape of the 120 thus measured proteotypes is displayed in Fig. 2A. All 195 technical replicates were clustered together using an unsupervised method based on the 196 quantified proteotypes, confirming high quantitative accuracy. In most cases, the proteotypes 197 are not strikingly different across different cancer cell lines, in sharp contrast with the distinct 198 proteomes of tumor versus non-tumor kidney tissues ⁷. The median coefficient of variation 199 (CV) of the protein intensity in different cells was 48%. The CV demonstrated a low 200 dependence on protein abundance, as evident from the distribution of its values for different 201 expression level quantile groups of the measured proteins (Fig. 2B). We then compared the 202 data acquired in this study with the DDA-MS proteomic data previously reported of the NCI-203 60 cells¹⁷. Whereas the DDA data reported comparable number of IPI protein groups to the 204 SwissProt proteotypic protein number from this SWATH data set per cell line 205

(Supplementary Table 2), the SWATH data exhibited much higher degree of consistency 206

207 (Supplementary Fig. 5) and better quantitative accuracy (Supplementary Fig. 6-7).

208



209

210

211 Figure 2. Characterizing NCI-60 quantitative proteomes. (A) Heatmap overview of NCI-60 proteotype data 212 matrix. 3,171 Swiss-Prot proteins were quantified in 120 SWATH runs. (B) Variation of protein expression, for 213 all proteins (All) and proteins in each abundance quantile group (from low abundance to high abundance). (C) 214 Density plot of correlation of determination between pairs of random proteins versus pairs of proteins within a 215 complex. (D) Stoichiometry variation of protein complexes in the NCI-60 cells. The x-axis shows the average 216 Pearson correlation of each protein complex across the NCI-60. The y-axis shows the average abundance of 217 proteins in a complex. Stable complexes tend to show higher values of average Pearson correlation. (E) Protein 218 and mRNA expression of XRCC6/Ku70 and XRCC5/Ku80. (F) Visualization of pathway activity in NCI-60 219 proteotypes. More detailed pathway annotations for this Google map are provided in Supplementary File 2. 220

Quantification of drug-responsiveness related proteins 221

222

The proteotypes covered 105 protein targets for FDA-approved anti-cancer 223

compounds, 661 protein drug targets annotated in DrugBank¹⁹ (including 68 drug 224

225	metabolizing enzymes, 5 drug carriers, and 15 drug transporters), 694 proteins known to
226	participate in human diseases ^{19, 20} , and 58 human protein kinases (Supplementary Table 3).
227	Some kinases were found to be broadly expressed in most cells with high abundance,
228	including MST4 and WNK1 (Supplementary Fig. 4), consistent with previous reports ^{21, 22} .
229	Other kinases were highly expressed in specific cell lines, for example, EGFR in the breast
230	cancer cell line MDAMB468, ERBB2 in SKOV3 cells, and CDK6 in MOLT4 cells, in
231	agreement with previous studies using antibody-based methods ^{20, 23} .
232	
233	A unique benefit of our proteomic data set, compared to genomic and transcriptomic
234	data, is its capacity to reveal more accurate information about the abundance of protein
235	complexes and their stoichiometry ²⁴ . Our measurements included 101 protein complexes
236	comprising 1,045 proteins (Supplementary Table 4) from a curated resource ²⁴ . Significantly
237	higher Pearson correlation coefficients for pairs of proteins that are part of a complex further
238	supported the quantitative accuracy of our data matrix (Fig. 2C). We applied our
239	computational pipeline for analyzing co-expression of protein complex numbers ²⁴ to the
240	NCI-60 proteotype data and confirmed conserved stoichiometry of protein complexes such as
241	the prefoldin and MCM complexes in various cell lines (Fig. 2D). In a specific case, we
242	observed a high correlation between the protein expression of XRCC6/Ku70 and
243	XRCC5/Ku80, a critical heterodimer involved in DNA repair and responsible for resistance to
244	radiotherapy and chemotherapy. Ku80 is degraded when not bound to Ku70 ^{25, 26} .
245	Remarkably, this correlation is not detectable using mRNA measurements (Fig. 2E),
246	indicating that expression of Ku80 is tightly regulated by protein degradation mechanisms
247	independent of cancer types. Indeed, a recent report has shown that RNF8, an E3 ubiquitin
248	ligase, regulates the expression of Ku80 via its removal from DNA double strand break sites
249	and its degradation through ubiquitination ²⁷ .
250	
251	Google-map-based visualization of cancer signaling pathways

252

The NCI-60 proteotypes cover 648 proteins in the Atlas of Cancer Signaling Networks (ACSN), a manually curated pathway database presenting published facts about biochemical reactions involved in cancer using a Google-Maps-style visualization (**Supplementary Fig. 8**) ²⁸. When mapping the mean protein expression per cancer type, we found that multiple pathways in different cell types, including apoptosis, cell survival, motility and DNA repair among others, displayed a similar pattern (**Supplementary File 2**), consistent with the fact

that the immortal cells retain cancer hallmarks after artificial culturing ²⁹. An example of a 259 clear proteotypic pattern is the delta isoenzyme of protein kinase C, *i.e.* PRKCD, involved in 260 DNA repair and a drug target that has been tested in various cancers ³⁰. It was reported to be 261 absent in four renal clear cell carcinoma lines ³¹. In agreement, this protein stood out in our 262 visualization, with significantly lower protein expression in renal carcinoma, relative to the 263 average expression in the NCI-60 panel. We provided detailed instructions on how to navigate 264 through the atlas and explore protein abundance in each cancer cell line (see Supplementary 265 266 **File 2**).

267

We next compared the activity of cellular pathways using ROMA (Representation and 268 quantification Of Module Activities)³² (Fig. 2F), a gene-set-based quantification algorithm. 269 This approach revealed substantial diversity of pathway activity between different proteotypes 270 as evidenced by two-tailed *t*-tests of activity scores (*P*-value < 0.05). When mapping activity 271 scores onto ACSN, some tissue specificities were revealed, with particular cell line 272 273 proteotypes displaying distinct patterns of pathway activity. For instance, the activity of apoptosis (with both Caspases and Apoptosis Genes modules) was found to be significantly 274 275 higher in ovarian cell lines (see Supplementary Table 5). Although there are only two prostate cancer cell lines in the panel, our analysis was able to highlight modules including 276 "AKT-mTOR" and "Apoptosis", whose differential activity can be attributed to HSP90AA1 277 and PRDX. The latter protein has been independently reported to be overexpressed in prostate 278 279 tumors ³³.

280

281 Accessibility of the NCI-60 proteotypes

282


To enable easy data access, visualization, and comparison with other NCI-60 data sets, 283 we have incorporated the SWATH data into the CellMiner database ^{13, 34}. CellMiner allows 284 the direct download of the data, as well as comparative and integrative analyses with other 285 286 molecular data and pharmacological data, e.g. sensitivity of each cell line to over 20,000 compounds, and the manual inspection of specific genes, up to 150 per query. The detailed 287 288 instructions for using this resource are provided on the project website (https://discover.nci.nih.gov/cellminer/) and in Supplementary Fig. 9. We have also 289 deposited raw data and processed data matrices of the NCI-60 proteotype in public databases, 290


including PRIDE 35 and ExpressionArray 36 .

293 Predicting drug responsiveness

294

The robust, quantitative proteomic data, with almost no missing values, permitted 295 296 systematic investigation of whether integration of the SWATH-based proteotype with existing 297 genomic and transcriptomic features improves the prediction of drug responsiveness (Supplementary Table 6). We generated various combinations of molecular features, and 298 evaluated their predictive power using the Pearson correlation between predicted and 299 observed drug response values for 240 FDA-approved or investigational compounds in 300 CellMiner ^{13, 34, 37}. Each compound is assigned a NSC (National Service Center) identifier 301 upon submission to the National Cancer Institute for evaluation in the NCI-60 panel. The 302 largest groups of drugs with target annotations are those that interfere with DNA synthesis 303 and the DNA damage response, including topoisomerase inhibitors. The drug set also contains 304 305 dozens of targeted agents, including 18 serine and threonine kinase inhibitors and 18 tyrosine kinase inhibitors (Fig. 3A). 306





Using the elastic net algorithm, we then developed multivariate linear models to predict the NCI-60 response for each compound based on genomic, transcriptomic and proteomic features. The Pearson's correlation between observed drug response values and leave-one-out cross validation-predicted response values was applied to evaluate the

- 322 performance of each predictive model.
- 323

As different numbers of features were measured for each omics data set, two strategies 324 were adopted in the modeling analyses. First, we used all omics features (2,282 DNA 325 326 mutations, 14,969 mRNAs and 3,171 proteins), separately and in combination, as inputs to 327 evaluate the general performance. Second, we selected 1,566 features that were available for 328 all three molecular data types (denoted as common features). In both cases, we obtained valid 329 models for 224 (93%) of the drugs. The predictive power achieved with all features was 330 slightly higher than that obtained using the common features for all three data types (Fig. 3A); a likely reason for this is that the latter excluded some genomic and transcriptomic features 331 332 not detected at the protein level. We accordingly derived our main analysis results from data 333 including all available molecular features. Our modeling led to the discovery of valid 334 biomarkers for drug responsiveness prediction. For instance, we found that the mRNA expression of SLFN11, strikingly responsible for the sensitivity of 45 compounds, out of 335 which 39 were FDA-approved drugs including topoisomerase inhibitors, alkylating agents, 336 and DNA synthesis inhibitors, was the most dominant indicator, in agreement with our 337 previous report ³⁸ (**Supplementary Table 7**). Fourteen ATP-binding cassette family 338 transporters, detected as mutation, transcript or protein levels, were found responsible for 339 sensitivity prediction of 51 compounds including chemotherapeutic agents and protein-340 targeting agents such as HDAC inhibitor Depsipeptide, HSP90 inhibitor Alvespimycin, 341 mTOR inhibitor Temsirolimus and BCR-ABL inhibitor Nilotinib (Supplementary Table 7). 342 343 For ease of reproducibility of data analysis, we developed a Docker container 344

345 (described in **Methods**) that includes our code and other essential dependencies, allowing all
346 analyses to be replicated and extended for this and other omics data sets.

- 347
- 348

349 Synergies among mutations, transcripts and proteins

Our pipeline led to the identification of valid models for 224 compounds 351 (Supplementary Table 7). Given the relatively small sample size, it was not surprising that 352 accurate predictive models could not be found for every drug, particularly those with limited 353 numbers of responsive lines. We found that the SWATH-MS derived proteotypes displayed a 354 higher percentage of predictive features than mutations and transcripts. 1,090 (34%) out of 355 3,171 SWATH features are predictive, while 284 (12%) out of 2,282 features for mutations 356 and 1,976 (13%) out of 14,969 transcripts were selected in the models. In general, the 357 358 SWATH data outperformed the mutation data, however, the mRNA expression data set has 359 about a five to six-fold higher number of features than the protein and mutation data sets (Fig. **3A**) and exhibited better overall performance (**Fig. 3C**). 360

361

Our analyses revealed notable synergies among the different molecular measurements. 362 363 Each type of molecular data set demonstrated indispensable benefits in predicting the response to certain drugs/compounds. The responsiveness of 35 compounds (16%) out of 224 364 365 was best predicted with SWATH data, whereas 107 compounds (48%) were best predicted by SWATH data or by combining SWATH data with transcripts and/or DNA data. The most 366 367 accurate models for over half of the compounds required at least two different types of molecular features. We then computed accumulative sum of Pearson correlation coefficient 368 based on drug responsiveness prediction and observed significant contribution of SWATH 369 data (Fig. 3D). We also compared the predictive power of the DDA data to the SWATH data. 370 While the DDA data were able to generate elastic net models for comparable number of drugs 371 (Fig. 3E), the number of protein predictors is much lower than SWATH data over some 372 overlap (Fig. 3F), indicating a higher degree of information content and robustness of the 373 374 signatures achieved with the SWATH data.

375

376 Drug responsiveness prediction

377

Based on the integration of various data sets, global drug response patterns were predicted for the 158 well-modeled drugs (**Fig. 4**, see Methods), with predictive molecular features for individual compounds provided in **Supplementary Table 7**. The data generated from this computational pipeline were validated by the recovery of established pharmacogenomic knowledge. For instance, the mutational status of BRAF was the top predictive molecular feature for sensitivity to BRAF inhibitors, *e.g.* vemurafenib (NSC 761431) and dabrafenib (NSC 764134), and this association was particularly evident in

- melanomas. Activated BRAF mutational status also sensitized cells to the MEK inhibitor
- hypothemycin (NSC: 354462), as has been previously described 39 .
- 387
- 388





Figure 4. Predictive power for 224 compounds using different types of omics data. We applied elastic net and
 cross validation to evaluate the drug response predictive accuracy for each omics data set and combinations of
 data sets for 224 drugs which could be effectively modeled. Drug response prediction accuracies across input
 data types are clustered without supervision. MoA of compounds and clinical status of the compounds are
 colored. Each column indicates an input data type or combination of types; each row represents a compound.

- 395 The color indicates the predictive power measured by Pearson correlation of cross-validation predicted versus
- 396 observed drug response values. Black indicates that a valid elastic net model could not be obtained.
- 397

Sensitivity to the antimetabolite 6-thioguanine (6-TG, NSC: 752) (Fig. 5A) was 398 399 predicted by expression levels of proteins NUDT5 and MAT2B within an elastic net model composed of 5 proteomic features: NUDT5, MAT2B, CD47, STX12 and GFAP. The cross-400 401 validation accuracy with this compound and the SWATH-MS data was relatively low (r = 0.27), probably due to instability in the selected predictive features with limited sample size. 402 403 Still, we find that for the two strongest predictors in the model, NUDT5 and MAT2B, the 404 expression data were significantly correlated with the activity of 6-TG (Fig. 5B and 5C). 405 Additionally, we were able to relate the inter-connected activities of these two proteins to the mechanism of action for 6-TG. In the purine salvage pathway, HPRT1 catalyzes synthesis of 406 inosine monophosphate from hypoxanthine and phosphoribosyl pyrophosphate (PRPP), with 407 production of the latter stimulated by NUDT5. 6-TG can substitute for hypoxanthine, 408 ultimately yielding altered nucleotides that are toxic upon incorporation into DNA ⁴⁰. PRPP is 409 still required, so low NUDT5 expression could possibly induce 6-TG resistance. This is 410 consistent with our NCI-60 data and recent experimental work showing that depletion of 411 NUDT5 confers resistance to 6-TG⁴¹. As noted in Fig. 5A, a metabolite of 6-TG, 412 413 thioguanosine monophosphate (TGMP) can be inactivated by methylation. Production of the 414 methyl group donor, S-adenosylmethionine (SAMe), is catalyzed by the methionine adenosyltransferase IIa (MAT2A) enzyme. The MAT2B protein, exhibiting high correlation 415 with MAT2A (Fig. 5D), is a regulatory component of MAT which may enhance feedback 416 inhibition by SAMe ⁴². Increased MAT inhibition and diminished TGMP methylation may 417 418 shunt more TGMP toward DNA incorporation, enhancing the 6-TG response. In spite of its relatively low cross-validation accuracy, the presented model may provide a starting point for 419 further exploration, in light of the supporting prior research. 420



422

Figure 5. Drug responsiveness predicted by SWATH data. (A) molecular mechanisms of 6TG. (B)
correlation between NUDT5 protein expression and 6-TG activity. (C) correlation between MAT2B protein
expression and 6-TG activity. (D) correlation between MAT2B and MAT2A protein expression. (E)
LAMTOR3 facilitates MEK/ERK pathway activation by binding MEK and ERK. (F) correlation between
LAMTOR3 protein expression and Vemurafenib activity. (G) Association of BRAF mutation and LAMTOR3
protein expression with Vemurafenib activity.

429

Analysis of the protein kinase inhibitor vemurafenib (NSC 761431) vielded a 430 multivariate model based on BRAF V600E activating mutation status ⁴³ and the protein 431 expression level of LAMTOR3. LAMTOR3 (MP1) is part of an endosomal scaffolding 432 complex that interacts with components of the RAF/MEK/ERK mitogenic signaling pathway 433 (Fig. 5E). In particular, LAMTOR3 binds MEK1 and ERK1, facilitating activation of the 434 latter protein ⁴⁴. Elevated LAMTOR3 protein expression was correlated with vemurafenib 435 resistance (r=0.44, Fig. 5F), consistent with the hypothesis that LAMTOR3 has the capacity 436 to enhance RAF/MEK/ERK pathway signaling downstream from RAF. In particular, 437 increased protein expression of LAMTOR3 was observed in two BRAF mutant cell lines, 438 ME:SK-MEL-5 and ME:LOXIMVI, which are relatively resistant to Vemurafenib (Fig. 5G). 439 Due to the limited number of cell lines in the NCI-60 compendium that contained BRAF 440 mutations exhibiting relative drug resistance (*i.e.* 2 cell lines), additional statistical analyses 441 with sufficient power were not possible. Robust statistical validation of this model may be 442

possible when larger cell line databases (e.g. the Sanger and Broad resources) expand to

443 include proteomic coverage of LAMTOR3. Still, this finding remains relevant in light of the 444 recent research into the activity of LAMTOR3, including the observation that reduced 445 LAMTOR3 protein levels decreased the activation of MEK1/2 and ERK1/2^{44,45}. 446 Additionally, LAMTOR3 has been shown to affect proliferation of pancreatic and breast 447 cancers ^{46, 47}, and has been patented as a diagnostic biomarker for breast cancer ⁴⁷. 448 449 Our elastic net analysis also produced multiple recurrent predictors with plausible drug 450 response associations. ABCC4 was a negatively weighted predictor for several alkylating 451 agents, including chlorambucil (NSC: 3088), uracil mustard (NSC: 34462), nitrogen mustard 452 (NSC: 762), consistent with its established role as a drug efflux pump ⁴⁸. Another recurrent, 453 negatively-weighted predictor was CTNND1, which was identified for several compounds, 454 455 including bendamustine (NSC: 138783), etoposide (NSC: 141540), valrubicin (NSC: 246131), and carmustine (NSC: 409962). CTNND1 encodes delta-catenin, whose 456 overexpression promotes cell survival through activation of Wnt pathway signaling ⁴⁹. The 457 resulting inhibition of apoptosis ⁵⁰ could plausibly confer resistance to the mentioned DNA-458

459 460

Discussion 461

damage inducing drugs.

462

Due to the complementarity of protein and transcript data ^{4-6, 51}, it can be expected that 463 the rapid and consistent quantification of thousands of proteins across a large sample cohort 464 will revel new biological information that is not apparent from the commonly used transcript 465 profiles. However, due to technical limitations, such proteomic cohort datasets have been 466 challenging to acquire. Here, using the NCI-60 cell line compendium, we demonstrate the 467 ability of the PCT-SWATH proteomic technique to consistently quantify in excess of 3000 468 proteins across the 60 cell lines measured in duplicate. The data were acquired in 30 working 469 470 days on a single mass spectrometer and for each sample measurement ca. 1 microgram of total peptide mass was consumed. This has been enabled by the pressure cycling technology 471 which minimizes samples consumption and the data-independent MS data acquisition using 472 SWATH-MS⁷. The data generated and their use to reveal cancer biology and drug response 473 determinants represent a significant advance in the field. 474

The proteome of the NCI-60 cells has been previously measured by extensive sample 476 fractionation and DDA-MS analysis of over 1,000 fractionated samples ¹⁷. In this study, data 477 acquisition for each cell line required an average of about 29.16 hours MS instrument time. 478 479 That shotgun proteomics study reported the cumulative identification of 10,350 IPI proteins over the NCI-60 cell lines. However, only 492 proteins were quantified in all cell lines 480 without missing value. The PCT-SWATH methodology adopted in this study offers an over 481 10-fold increase in sample-throughput, which has allowed us to acquire the proteotype for 482 each cell in the NCI-60 panel in duplicate, with standardized sample preparation, within 30 483 working days. In addition, our data have 0.1% amount of missing values at protein level 484 owing to the data acquisition strategy and improvements in bioinformatics analysis. This 485 study demonstrates that the human proteotype can be obtained with a throughput comparable 486 to genomic and transcriptomic analyses, though still at relatively lower coverage. 487

488

Two aspects of our workflow ensure robust and quantitatively accurate protein 489 490 expression measurements. First, we obtained technical duplicates for the entire set of NCI-60 proteotypes, which was feasible due to the unparalleled high sample-throughput of the PCT-491 492 SWATH methodology which is now gaining popularity in proteomic profiling of clinical specimens. In addition, we developed an expert system software (manuscript in preparation) 493 to further curate peptide and protein identification and quantification. Applying stringent 494 criteria, 3,171 proteins were included for further analyses. The raw MS signal for each of 495 these quantified proteins, in each cell line, was inspected by the expert system, simulating 496 manual inspection, and is available for visual inspection in the supplementary data. We further 497 compared the expression of a few proteins with known expression in certain cell lines, 498 obtaining good agreement. Nevertheless, we cannot conclude that the peptides and proteins 499 500 that failed to pass curation by the expert system are not biological signals, due to the 501 unpredictable degree of biological heterogeneity, and the fact that we did not analyze noncanonical peptide variants and post-translational modification. The latter can be potentially 502 503 dissected and quantitated by future in silico analyses of our SWATH maps. Since the NCI-60 cell lines are widely used in cell biology, we anticipate broad utility of this highly curated 504 proteomic data. Additionally, our rapid proteotype acquisition pipeline using PCT-SWATH 505 requires little biological material, making it suitable for clinical settings and in precision 506 medicine efforts 7, 8, 52. 507

Compared to other omics data, the proteotypes obtained here offered unique insights 509 into the coordinated expression of protein complexes. Interactions amongst their component 510 subunits contribute to our understanding of protein function, as well as human diseases ^{24, 53-} 511 ⁵⁵. Several protein complexes have been identified as biomarkers of disease, including cancer 512 progression ⁵⁶. Our high quality proteomic data allowed systematic investigation of the 513 composition of 101 protein complexes in 60 cell lines. We expect that this represents a proof-514 of-principle for a generic, high-throughput approach, applicable to clinical specimens⁷, for 515 exploring the association between protein complexes and biological/disease phenotypes. 516

517

518 The NCI-60 continues to enable important contributions that have come and continue to come from this resource, and often emerging technologies are first tested on this cell line 519 panel due to its diversity and depth of surrounding knowledge ^{3, 12, 57-59}. Each cancer cell line 520 521 in the NCI-60 has been tested against tens of thousands of compounds, including the 240 FDA-approved and investigational drugs featured in our analyses. With the addition of the 522 523 SWATH proteomic data, the NCI-60 remains positioned as one of most comprehensive models for cancer research and drug discovery ^{12, 15}. It uniquely enabled our thorough, 524 525 integrative analysis of different molecular profiles (genomic, transcriptomic, and proteomic) in predicting drug responsiveness. Our findings strengthen the body of work highlighting the 526 importance of integrative omic approaches in understanding drug mechanisms and establish 527 the benefit of large-scale proteomic measurements. Therefore, we expect this work to become 528 a seminal work in the area of pharmacoproteomics, the benefit of which will grow with 529 anticipated expansion of sample size, proteomic coverage, including extension to 530 phosphoproteomic expression, as well as extension to mouse models ⁶⁰ and human specimens 531 7 532

533

The existing SWATH data specifically enabled the use of advanced analysis 534 techniques to produce multivariate models of drug response. Great effort was put into making 535 536 our work accessible to a large audience through data submission to the NCI-60 CellMiner database and availability through an accompanying R package, rcellminer. We expect this 537 538 pipeline based on the widely used elastic net method will continue to evolve and enable future 539 studies on additional data sets and phenotypes. And while the strengths of the elastic net method over other related methods have been previously described ^{61, 62}, the resulting models 540 still require careful scrutiny by individual researchers. The interpretation of the models 541 542 developed here, and by others using our pipeline, should be guided by understanding of the

biological activities of the associated predictors in the context of the mechanisms of action for 543 the input drugs. From the models generated by the current analyses, we identified several 544 potential determinants of drug responses, including NUDT5 and MAT2B protein levels for 545 the antimetabolite 6-TG, as well as complementary markers, such as LAMTOR3 protein 546 levels in conjunction with BRAF mutational status for Vemurafenib and other BRAF 547 inhibitors. These determinants may provide clinically relevant insights toward understanding 548 mechanisms of resistance to these and other agents. Together, these results invite further 549 investigation of this unique proteomic data resource. For example, the analysis of protein 550 551 complexes in the current study identified discrepancies between data at the transcriptomic and proteomic levels. This observation has been similarly made in tumor samples, with additional 552 variation across tissue types ⁶³. These differences can be used in future studies to develop 553 drug response models with non-redundant predictor sets including both data types. However, 554 555 due to the tissue diversity of the NCI-60 cells and the limited number of cell lines, data from a higher number of cancer cell lines of specific tissue type and extension to clinical specimens 556 557 are required to advance our findings to clinical applications.

558

559 Acknowledgements

We thank Margot Sunshine who developed CellMiner and the NCI-DTP team (Dr. 560 Jerry Collins and Dr. James H. Doroshow) for the drug data and support for data acquisition, 561 Emanuel Goncalves for comments to the manuscript. The work was supported by the 562 SystemsX.ch project PhosphoNetX PPM (to R.A.), the Swiss National Science Foundation 563 (grant no. 3100A0-688 107679 to R.A.), the European Research Council (grants no. ERC-564 565 2008-AdG 233226 and ERC-20140AdG 670821 to R.A.), the Ruth L. Kirschstein National Research Service Award (grant no. F32 CA192901 to A.L.), the National Resource for 566 567 Network Biology (NRNB) from the National Institute of General Medical Sciences (NIGMS) (grant no. P41 GM103504 to C.S.), and the Center for Cancer Research, Intramural Program 568 of the National Cancer Institute (grant no. Z01 BC006150 to Y.P), and the Wellcome Trust 569 Award (102696) to M.J.G. We thank An Guo for help in preparing the graphics. 570

571

572 Author contributions

T.G. designed and coordinated the project with supervision from R.A. C.C.K.
processed the samples. L.G., C.C.K. and T.G. acquired the SWATH data. T.G. performed the
SWATH data interpretation and benchmarking with help from C.C.K., and the expert system
analysis with help from U.S. A.L., V.N.R. and Z.W. performed the drug response prediction

- analysis, and developed the reproducible research infrastructure, with critical inputs from
- 578 M.P.M., J.S.R., M.J.G., S.V., W.C.R., C.S, and Y.P., L.C. and L.M. performed the pathway
- analysis. A.L., V.N.R., W.C.R. and S.V. integrated the SWATH data into rcellminer and
- 580 CellMiner. A.O., M.I. and R.C. performed the protein complex analysis, with help from A.L.,
- 581 Z.W., Y.C., V.N.R, C.S., Y.S., Y.Z., Y.P. P.Q. and Q.Z. contributed to the data analysis.
- 582 T.G., A.L. and V.N.R. wrote the manuscript with inputs from all co-authors. P.J.W., P.B.,
- 583 M.R., J.S.R., W.C.R., C.S., Y.P. and R.A. supervised the project.
- 584

585 **Competing financial interests**

586 R.A. holds shares of Biognosys AG, which operates in the field covered by the article.

587 The research group of R.A. is supported by SCIEX, which provides access to prototype

- instrumentation, and Pressure Biosciences, which provides access to advanced sample
- 589 preparation instrumentation.
- 590

592 Materials and Methods

593

594 PCT-assisted sample preparation for MS analyses

595

The NCI-60 cells were obtained as frozen, non-viable cell pellets from the 596 Developmental Therapeutics Program (DTP), National Cancer Institute (NCI-NIH) and 597 processed using Barocycler® NEP2320 (PressureBioSciences Inc, South Easton, MA). The 598 IDs of the NCI-60 cells in our study matching to the IDs in Cellminer and a previous 599 proteomic study by the Kuster group are provided in Supplementary Table 1. Briefly, cell 600 pellets were lysed in a buffer containing 8M urea, 0.1M ammonium bicarbonate, and 601 CompleteTM protease inhibitor using barocycler program (20 seconds 45 kpsi, 10 seconds 0 602 kpsi, 120 cycles) at 35°C⁷. Whole cell lysates were sonicated for 25 seconds with 1 min 603 interval on ice for 3 times. Cellular debris was removed by centrifugation and sample protein 604 605 concentration was determined by BCA assay prior to protein reduction with 10 mM TCEP for 20 min at 35°C, and alkylation with 40 mM iodoacetamide in the dark for 30 min at room 606 607 temperature. Lys-C digestion (1/50, w/w) was performed in 6 M urea using PCT program (25 seconds 25 kpsi, 10 seconds 0 kpsi 75 cycles) at 35°C; whereas trypsin digestion (1/30, w/w) 608 609 was performed in further diluted urea (1.6M) using PCT program (25 seconds 25 kpsi, 10 seconds 0 kpsi, 160 cycles) at 35°C. Digestion was stopped by acidification with 610 611 trifluoroacetic acid to a final pH of around 2 before C18 column desalting using SEP-PAK 612 C18 cartridges (Waters Corp., Milford, MA, USA). 613

614 Off-gel electrophoresis

615

To create a comprehensive spectral library for SWATH-MS analysis, we pooled 20-616 617 40% of desalted peptide solutions from each NCI-60 sample and performed off-gel fractionation. Briefly, pooled peptides were resolubilised in OGE buffer containing 5% (v/v)618 glycerol, 0.7% (v/v) acetonitrile (ACN) and 1% (v/v) carrier ampholytes mixture (IPG buffer 619 pH 3.0-10.0, GE Healthcare). Fractionation was performed on a 3100 OFFGEL (OGE) 620 Fractionator (Agilent Technologies) using a 24 cm pH3-10 IPG strip (Immobilised pH 621 622 Gradient strip from GE Healthcare) according to manufacturer's instructions using a program of 1 h rehydration at a maximum of 500 V, 50 µA and 200 mW followed by separation at a 623 maximum of 8000 V, 100 µA and 300 mW until 50 kVh were reached. Each of 24 fraction 624 was recovered and cleaned up by C18 reversed-phase MicroSpin columns (The Nest Group 625

Inc.). Based on the sample complexity (based on Nanodrop, A280 measurement), for each

- strip, the following fractions were pooled into 12 samples for MS injections: pool 1 (fraction
- 628 1-2), pool 2 (fraction 3), pool 3 (fraction 4), pool 4 (fraction 5), pool 5 (fraction 6-7), pool 6
- 629 (fraction 8-9), pool 7 (fraction 10-11), pool 8 (fraction 12-15), pool 9 (fraction 16-19), pool 10
- 630 (fraction 20-21), pool 11 (fraction 22), pool 12 (fraction 23-24). Those were injected in
- 631 quadruplicate, resulting in 48 DDA injections of fractionated samples.
- 632

633 DDA MS for spectral library generation

634

For spectral library generation, a SCIEX TripleTOF 5600 System mass spectrometer 635 was operated essentially as described before ⁶⁴: all samples were analyzed on an Eksigent 636 nanoLC (AS-2/1Dplus or AS-2/2Dplus) system coupled with a SWATH-MS-enabled AB 637 638 SCIEX TripleTOF 5600 System. The HPLC solvent system consisted of buffer A (2% ACN and 0.1% formic acid, v/v) and buffer B (95% ACN with 0.1% formic acid, v/v). Samples 639 were separated in a 75 µm diameter PicoTip emitter (New Objective) packed with 20 cm of 640 Magic 3 µm, 200A C18 AQ material (Bischoff Chromatography). The loaded material was 641 eluted from the column at a flow rate of 300 nL min⁻¹ with the following gradient: linear 2 -642 35% B over 120 min, linear 35 - 90% B for 1 min, isocratic 90% B for 4 min, linear 90 - 2% 643 B for 1 min and isocratic 2% solvent B for 9 min. The mass spectrometer was operated in 644 DDA mode using a top20 method, with 500 ms and 150 ms acquisition time for the MS1 and 645 MS2 scans respectively, and 20 s dynamic exclusion for the fragmented precursors. Rolling 646 collision energy using the following equation $(0.0625 \times m/z - 3.5)$ with a collision energy 647 spread of 15 eV was used for fragmentation regardless of the charge state of the precursors, to 648 mimic as close as possible the fragmentation conditions of the precursors in SWATH-MS 649 mode. Altogether, we had 66 DDA-MS injections, including the 48 OGE samples and another 650 18 pooled peptide samples from the unfractionated cell lysate of the NCI-60 cells. 651

652

653 Spectral and assay library generation

654

All raw instrument data were centroided using Proteowizard msconvert (version 2.0).

656 The assay library was generated using an established protocol ⁶⁴. In short, the shotgun data

sets were searched individually using X!Tandem 65 (2011.12.01.1) with k-score plugin 66 ,

658 Myrimatch ⁶⁷ (2.1.138), OMSSA ⁶⁸ (2.1.8) and Comet ⁶⁹ (2013.02r2) against the reviewed

659 UniProtKB/Swiss-Prot (2014_02) protein sequence database containing 20,270 proteins

appended with 11 iRT peptides and decoy sequences. Carbamidomethyl was used as a fixed 660 661 modification and oxidation as the variable modification. Maximally two missed cleavages were allowed. Peptide mass tolerance was set to 50 ppm, fragment mass error to 0.1 Da. The 662 search identifications were combined and statistically scored using PeptideProphet⁷⁰ and 663 iProphet⁷¹ available within the Trans-Proteomics Pipeline (TPP) toolset (version 4.7.0)⁷². 664 MAYU⁷³ (v. 1.07) was used to determine the iProphet cutoff (0.999354) corresponding to a 665 protein FDR of 1.03%. SpectraST was used in library generation mode with CID-QTOF 666 settings and iRT normal-isation at import against the iRT Kit ⁷⁴ peptide sequences (-667 c_IRTirt.txt -c_IRR) and a consensus library was consecutively generated. An in-house 668 python script, spec-trast2tsv.py31 (msproteomicstools 0.2.2) was then used to generate the 669 assay library with the following settings: -1 350,2000 -s b,y -x 1,2 -o 6 -n 6 -p 0.05 -d -e -w 670 swath32.txt -k openswath (fragment ions between 350 and 2000 m/z, b and y ions authorized, 671 672 fragment charges 1+ and 2+, 6 most intense transitions, precision of fragment ion retrieved 0.05 Da, exact fragment ion mass calculated, exclude fragments in the swath window). The 673 674 OpenSWATH tool, ConvertTSVToTraML converted the TSV file to TraML format; Open-SwathDecoyGenerator generated the decoy assays in shuffle mode and appended them to the 675 676 TraML assay library. In this study, we built a SWATH assay library containing 86,209 proteotypic peptide precursors in 8.056 proteotypic SwissProt proteins. This library is 677 supplied in PRIDE project PXD003539. 678

679

680 SWATH-MS

681

The SWATH-MS data acquisition in a Sciex TripleTOF 5600 mass spectrometer was performed as described before ¹⁰, using 32 windows of 25 Da effective isolation width (with an additional 1 Da overlap on the left side of the window) and with a dwell time of 100 ms to cover the mass range of 400 - 1200 m/z in 3.3 s. The collision energy for each window was set using the collision energy of a 2+ ion centered in the middle of the window (equation: 0.0625 x m/z - 3.5) with a spread of 15 eV. The sequential precursor isolation window setup was as follows: [400-425], [424-450], [449-475], ..., [1174-1200].

689

690 Protein identification using OpenSWATH

691

We analyzed the SWATH data using OpenSWATH software ¹¹ using parameters as
 described previously ²⁴. We identified 48,374 peptides from 6,556 protein groups from the

NCI-60 panel with < 1% false discovery rate at both peptide and protein level evaluated by
OpenSWATH ¹¹and Mayu ⁷⁵ (supplied in PRIDE project PXD003539).

696

697 **DIA-expert analyses**

698

The DIA-expert software read OpenSWATH output result file which contains 699 statistical scores (i.e. mProphet score or mScore) indicating the confidence of identification 700 for each peptide precursor in each sample, and from there selected the sample in which a 701 702 peptide precursor was identified with highest confidence. It then obtained extracted ion 703 chromatograms (XICs) for the target peptide precursor and all associated annotated b and y fragments in the reference sample, and refined fragments based on the peak shape of each 704 705 fragment and its peak boundary. The refined fragments and precursor XIC traces from each of 706 the rest samples were subsequently compared with the reference peak group using empirical expert rules, based on which the best matched peak group in each sample was picked and 707 708 visualized. Duplicated measurements were used to evaluate the accuracy of peptide and protein quantification. The protein quantity was normalized based on total ion 709 710 chromatography of the MS1 spectra from each raw SWATH file. All codes are provided in 711 Github https://github.com/tiannanguo/dia-expert.

712

713 **Protein complexes analysis**

714

For this analysis, technical replicates were averaged to generate the NCI-60 715 proteotypes. To assess the coverage of protein complexes by NCI-60 proteotypes, we 716 retrieved a large resource of mammalian protein complexes assembled from CORUM ⁷⁶, 717 COMPLEAT ⁷⁷ and literature-curated complexes ^{24, 78}. This resource contains 2,041 proteins 718 as members of 279 distinct complexes and it is available at http://variablecomplexes.embl.de/. 719 101 complexes were represented in the NCI-60 proteotypes with at least 5 members 720 721 quantified. These complexes, in total, contain 1,045 distinct proteins quantified in the NCI-60 proteotypes. Pearson's correlation coefficient was calculated for all the pairwise comparisons 722 723 of 3,171 proteins across the NCI-60 cell lines. All pairwise comparisons were classified into two categories: either two proteins were members of the same complex or not. Average 724 725 abundance, standard deviation and average Pearson correlation of each complex were calculated based on the abundance of complex members in the NCI-60 proteotypes. 726 727

For this analysis, technical replicates were averaged to generate the NCI-60 728 729 proteotypes. To assess the coverage of protein complexes by NCI-60 proteotypes, we retrieved a large resource of mammalian protein complexes assembled from CORUM ⁷⁶, 730 COMPLEAT ⁷⁷ and literature-curated complexes ^{24, 78}. This resource contains 2041 proteins 731 as members of 279 distinct complexes and it is available at http://variablecomplexes.embl.de/. 732 733 158 complexes were represented in the NCI-60 proteotypes with at least 5 members quantified. These complexes, in total, contain 1,045 distinct proteins quantified in the NCI-60 734 proteotypes. Pearson's correlation coefficient was calculated for all the pairwise comparisons 735 736 of 3,171 proteins across the NCI-60 cell lines. All pairwise comparisons were classified into 737 two categories: either two proteins were members of the same complex or not. Average 738 abundance and standard deviation of each complex were calculated based on the mean 739 abundance of complex members in the NCI-60 proteotypes. 740

741 Pathway activity analysis

742

The activity of pathways, as they are described in ACSN, has been computed using 743 744 ROMA ³². Among all the modules defined in ACSN, only 11 show a significant dispersion over the data set: AKT_MTOR, HR (Homologous Recombination), NER (nucleotide 745 Excision Repair), TNF response, Death Receptors regulators, Apoptosis, caspases, E2F3 and 746 E2F4 targets, HIF1 and cytoskeleton polarity. For these modules, the mean activity score for 747 each type of cancer cell lines was computed and mapped onto the atlas (from bright green for 748 low values to bright red for high values). To assess module differential activity between 749 750 proteotypes, we computed a *t*-test on the activity scores in cell lines of a cancer type versus 751 the activity of all other cancer cell lines. The definition of genes composing each module can 752 be found in http://acsn.curie.fr

- 753
- 754

755 Drug sensitivity prediction using elastic net

756

The elastic net regularized regression algorithm was applied to predict drug response for 240 FDA-approved or investigational NSC-designated compounds. Some widely studied drugs are represented by more than one NSC identifier, with each identifier associated with a distinct compound sample and series of NCI-60 drug activity assays. For each compound, 7 combinations of input data were evaluated. These included NCI-60 mRNA expression, gene-

level mutation, and SWATH-MS protein expression, both alone and in all possible 762 763 combinations. mRNA expression data was available for 14,969 genes, and derived from CellMiner, with missing values imputed using the impute.knn function (with default 764 parameters) of the Bioconductor impute package. Gene-level mutation profiles were 765 available for 2,282 genes, and were obtained from CellMiner exome sequencing data, with 766 767 values indicating the percent conversion to a variant form for the case of expected functionimpacting alterations (frameshift, nonsense, splice-sense, missense mutations by 768 SIFT/PolyPhen2 analysis). SWATH-MS based protein expression data was available for 769 770 3,171 proteins.

771

Elastic net analysis was done using the glmnet R package ⁷⁹. The elastic net analysis was conducted using a multi-step pipeline involving cross-validations performed in a nested manner. The "outer" cross-validation is a leave-one-out cross validation that is conducted over all computational steps present in the "inner" pipeline, and it is used to validate model performance. The "inner" cross-validation are conducted to select elastic net hyperparameters (alpha and lambda) and for predictor set trimming, using data from a set of ~59 cell lines.

779 The elastic net parameters alpha and lambda were selected by minimizing the crossvalidation error (average of 10 replicates of 10-fold cross-validation) within the "inner" 780 pipeline. The selected alpha and lambda parameters were then applied to 200 runs of the 781 elastic net algorithm, each using a random data subset derived from 90% of the available cell 782 lines. The 200 resulting coefficient vectors were then averaged, and predictors were ranked by 783 the magnitude of their average coefficient weight. To select a limited number of predictors 784 with potential to generalize to new data, top k-element predictor sets (by average coefficient 785 786 weight magnitude) were evaluated using standard linear regression and 10-fold crossvalidation. The appropriate k was set to the smallest value yielding a cross-validation error 787 within one standard deviation of the minimum cross-validation error. 788

789

To obtain a robust estimate of performance on unseen data, leave-one-out crossvalidation was applied to the overall procedure as part of the "outer" pipeline. Specifically, drug response for each cell line was predicted using an elastic net model derived using the remaining held out data (and the steps outlined above). The vector of predicted response values was then correlated with the actual response values, with the Pearson's correlation

- coefficient providing an estimate of the predictive value of the applied input data
- combination. More details of the elastic net algorithm are provided in File S3.
- 797

798 Elastic net analysis was done using the rcellminerElasticNet R package

799 (<u>https://bitbucket.org/cbio_mskcc/rcellminerelasticnet</u>), which facilitates the application of the

- glmnet R package (which provides the elastic net algorithm code) to data from the rcellminer
- and rcellminerData packages ⁸⁰. rcellminerElasticNet also provides utility functions for
- summarizing and visualizing elastic net results.
- 803

804

Results for the elastic net analysis are available from this URL:

 $\label{eq:https://discover.nci.nih.gov/cellminerreviewdata/swath_analysis/swathOutput_062316_all.tar.$

gz. This compressed file contains results for the analysis run with all features and selected

807 common features. Each drug compound has three files for each combination of molecular

features used in a particular run of the elastic net algorithm: 1) a knitr report R Markdown

809 (.Rmd) file containing the code that was run, 2) an RData (.Rdata) file containing the results

- 810 of each elastic net run (see elasticNet() documentation in the rcellminerElasticNet package),
- 811 3) the rendered knitr report as a webpage (.html).
- 812

Beyond the knitr report containing code, the elastic net pipeline is made reproducible using a Docker image. Docker (www.docker.com) is an emerging platform for conducting reproducible research in the biomedical research community. All necessary software and dependencies to run the described analysis have been embedded in the available Docker container to provide readers an environment that runs on all major operating systems (including Windows, OSX, and Linux), making Docker containers self-contained, portable, and capable of performing at levels similar to the host system.

820

The Docker container is available at the Docker Hub repository: cannin/swath (https://hub.docker.com/r/cannin/swath/). Key dependencies installed, include: RStudio Server (https://www.rstudio.com/), rcellminer/rcellminerData ⁸⁰, and rcellminerElasticNet. With these installed dependencies, readers have the opportunity to 1) re-run analysis for specific drug compounds and modify the code in order to extend the analysis using RStudio Server, a web-based version of the RStudio R editor, and 2) use an R Shiny app web-based data explorer to further understand described results. Instructions on the usage of the Docker

828	container are located at the rcellminerElasticNet project page
829	(https://bitbucket.org/cbio_mskcc/rcellminerelasticnet).
830	
831	Data deposition
832	
833	The NCI-60 SWATH data sets and SWATH assay library has been deposited in
834	PRIDE. Project Name: NCI60 proteome by PCT-SWATH; Project accession: PXD003539.
835	Reviewer account details:
836	Username: reviewer15254@ebi.ac.uk
837	Password: dWdyptzf
838	The protein data matrix has also been deposited in ArrayExpress. Project accession: E-
839	PROT-2. Project title: Proteomic profiling of NCI60 cell lines from Cancer Cell Line
840	Encyclopedia.
841	Reviewer account details:
842	Username: Reviewer_E-PROT-2
843	Password: gdgywGco
844	The protein data matrix is also accessible in CellMiner website ¹³ and R package
845	rcellminer ³⁷ .

Cancer Genome Atlas Research, N. et al. The Cancer Genome Atlas Pan-Cancer analysis

847 **References**

1.

848

850		project. <i>Nat Genet</i> 45 , 1113-1120 (2013).
851	2.	Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of
852		anticancer drug sensitivity. Nature 483, 603-607 (2012).
853	3.	Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer
854		cells. Nature 483 , 570-575 (2012).
855	4.	Zhang, B. et al. Proteogenomic characterization of human colon and rectal cancer. Nature
856		513 , 382-387 (2014).
857	5.	Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer.
858		Nature 534 , 55-62 (2016).
859	6.	Zhang, H. et al. Integrated Proteogenomic Characterization of Human High-Grade Serous
860		Ovarian Cancer. Cell (2016).
861	7.	Guo, T. et al. Rapid mass spectrometric conversion of tissue biopsy samples into permanent
862		quantitative digital proteome maps. <i>Nat Med</i> (2015).
863	8.	Shao, S. et al. Minimal sample requirement for highly multiplexed protein quantification in
864		cell lines and tissues by PCT-SWATH mass spectrometry. <i>Proteomics</i> (2015).
865	9.	Powell, B.S., Lazarev, A.V., Carlson, G., Ivanov, A.R. & Rozak, D.A. Pressure cycling technology
866		in systems biology. <i>Methods Mol Biol</i> 881, 27-62 (2012).
867	10.	Gillet, L.C. et al. Targeted data extraction of the MS/MS spectra generated by data-
868		independent acquisition: a new concept for consistent and accurate proteome analysis.
869		Molecular & cellular proteomics : MCP 11 , O111 016717 (2012).
870	11.	Rost, H.L. et al. OpenSWATH enables automated, targeted analysis of data-independent
871		acquisition MS data. Nat Biotechnol 32 , 219-223 (2014).
872	12.	Shoemaker, R.H. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer
873		6 , 813-823 (2006).
874	13.	Reinhold, W.C. et al. CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to
875		Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set. Cancer Res 72, 3499-3511
876		(2012).
877	14.	Fojo, T. et al. Identification of non-cross-resistant platinum compounds with novel
878		cytotoxicity profiles using the NCI anticancer drug screen and clustered image map
879		visualizations. Crit Rev Oncol Hematol 53, 25-34 (2005).
880	15.	Holbeck, S.L., Collins, J.M. & Doroshow, J.H. Analysis of Food and Drug Administration-
881		approved anticancer agents in the NCI60 panel of human tumor cell lines. <i>Mol Cancer Ther</i> 9,
882		1451-1460 (2010).
883	16.	Bates, S.E. et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic
884		implications from clinical and correlative data. Br J Haematol 170 , 96-109 (2015).
885	17.	Gholami, A.M. et al. Global Proteome Analysis of the NCI-60 Cell Line Panel. Cell Rep 4, 609-
886		620 (2013).
887	18.	Picotti, P. & Aebersold, R. Selected reaction monitoring-based proteomics: workflows,
888		potential, pitfalls and future directions. Nat Methods 9 , 555-566 (2012).
889	19.	Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42,
890		D1091-1097 (2014).
891	20.	Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347,
892		1260419 (2015).
893	21.	Lin, J.L. et al. MST4, a new Ste20-related kinase that mediates cell growth and transformation

- 89321.Lin, J.L. et al. MST4, a new Ste20-related kinase that mediates cell growth and transformation894via modulating ERK pathway. Oncogene 20, 6559-6569 (2001).
- Huang, C.L., Cha, S.K., Wang, H.R., Xie, J. & Cobb, M.H. WNKs: protein kinases with a unique kinase domain. *Exp Mol Med* **39**, 565-573 (2007).

897	23.	Xu, H. et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple
898		members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 4, 435-442
899		(2005).
900	24.	Ori, A. et al. Spatiotemporal variation of mammalian protein complex stoichiometries.
901		Genome Biol 17 , 47 (2016).
902	25.	Kanungo, J. Exogenously expressed human Ku70 stabilizes Ku80 in Xenopus oocytes and
903		induces heterologous DNA-PK catalytic activity. <i>Mol Cell Biochem</i> 338 , 291-298 (2010).
904	26.	Chang, H.W. et al. Effect of beta-catenin silencing in overcoming radioresistance of head and
905		neck cancer cells by antagonizing the effects of AMPK on Ku70/Ku80. Head Neck 38 Suppl 1 ,
906		E1909-1917 (2016).
907	27.	Feng, L. & Chen, J. The E3 ligase RNF8 regulates KU80 removal and NHEJ repair. Nat Struct
908		Mol Biol 19 , 201-206 (2012).
909	28.	Kuperstein, I. et al. Atlas of Cancer Signalling Network: a systems biology resource for
910		integrative analysis of cancer data with Google Maps. Oncogenesis 4, e160 (2015).
911	29.	Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. <i>Cell</i> 144, 646-674
912		(2011).
913	30.	Mackay, H.J. & Twelves, C.J. Targeting the protein kinase C family: are we there yet? Nat Rev
914		Cancer 7 , 554-562 (2007).
915	31.	Engers, R. et al. Protein kinase C in human renal cell carcinomas: role in invasion and
916		differential isoenzyme expression. Br J Cancer 82, 1063-1069 (2000).
917	32.	Martignetti, L., Calzone, L., Bonnet, E., Barillot, E. & Zinovyev, A. ROMA: Representation and
918		Quantification of Module Activity from Target Expression Data. Front Genet 7, 18 (2016).
919	33.	Ummanni, R. et al. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and
920		affect the proliferation of prostate cancer cells in vitro. <i>J Proteome Res</i> 11 , 2452-2466 (2012).
921	34.	Shankavaram, U.T. et al. CellMiner: a relational database and query tool for the NCI-60
922		cancer cell lines. <i>BMC genomics</i> 10 , 277 (2009).
923	35.	Jones, P. et al. PRIDE: a public repository of protein and peptide identifications for the
924		proteomics community. <i>Nucleic Acids Res</i> 34 , D659-663 (2006).
925	36.	Brazma, A. et al. ArrayExpressa public repository for microarray gene expression data at the
926	27	EBI. Nucleic Acids Res 31 , 68-71 (2003).
927	37.	Luna, A. et al. rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in B. Biginformatics (2015)
928 929	20	lines in R. <i>Bioinformatics</i> (2015).
929 930	38.	Zoppoli, G. et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. <i>Proc Natl Acad Sci U S A</i> 109 , 15030-15035 (2012).
930 931	20	Solit, D.B. et al. BRAF mutation predicts sensitivity to MEK inhibition. <i>Nature</i> 439 , 358-362
931	39.	(2006).
932 933	40.	de Boer, N.K., van Bodegraven, A.A., Jharap, B., de Graaf, P. & Mulder, C.J. Drug Insight:
933 934	40.	pharmacology and toxicity of thiopurine therapy in patients with IBD. <i>Nat Clin Pract</i>
935		Gastroenterol Hepatol 4 , 686-694 (2007).
936	41.	Doench, J.G. et al. Optimized sgRNA design to maximize activity and minimize off-target
937	71.	effects of CRISPR-Cas9. Nat Biotechnol 34 , 184-191 (2016).
938	42.	Halim, A.B., LeGros, L., Geller, A. & Kotb, M. Expression and functional interaction of the
939	72.	catalytic and regulatory subunits of human methionine adenosyltransferase in mammalian
940		cells. <i>The Journal of biological chemistry</i> 274 , 29720-29725 (1999).
941	43.	Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. <i>The New</i>
942	101	England journal of medicine 363 , 809-819 (2010).
943	44.	Schaeffer, H.J. et al. MP1: a MEK binding partner that enhances enzymatic activation of the
944		MAP kinase cascade. <i>Science</i> 281 , 1668-1671 (1998).
945	45.	Teis, D., Wunderlich, W. & Huber, L.A. Localization of the MP1-MAPK scaffold complex to
946		endosomes is mediated by p14 and required for signal transduction. <i>Dev Cell</i> 3 , 803-814
947		(2002).
948	46.	Jun, S. et al. PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic
949	-	tumorigenesis. <i>Cell Rep</i> 5 , 314-322 (2013).
		33

950	47.	De Araujo, M.E. et al. Polymorphisms in the gene regions of the adaptor complex
951		LAMTOR2/LAMTOR3 and their association with breast cancer risk. PLoS One 8, e53768
952		(2013).
953	48.	Borst, P. & Elferink, R.O. Mammalian ABC transporters in health and disease. Annu Rev
954		Biochem 71 , 537-592 (2002).
955	49.	Tang, B. et al. Overexpression of CTNND1 in hepatocellular carcinoma promotes carcinous
956		characters through activation of Wnt/beta-catenin signaling. <i>J Exp Clin Cancer Res</i> 35 , 82
957	50	
958	50.	Chen, S. et al. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-
959	- 4	mediated transcription. <i>J Cell Biol</i> 152 , 87-96 (2001).
960	51.	Liu, Y., Beyer, A. & Aebersold, R. On the Dependency of Cellular Protein Levels on mRNA
961 062	52	Abundance. <i>Cell</i> 165 , 535-550 (2016).
962 062	52.	Shao, S. et al. Reproducible Tissue Homogenization and Protein Extraction for Quantitative
963 964		Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology. <i>J Proteome Res</i> 15 , 1821-1829 (2016).
964 965	53.	Dudley, A.M., Janse, D.M., Tanay, A., Shamir, R. & Church, G.M. A global view of pleiotropy
965	55.	and phenotypically derived gene function in yeast. <i>Mol Syst Biol</i> 1 , 2005 0001 (2005).
967	54.	Wang, Q. et al. Community of protein complexes impacts disease association. <i>Eur J Hum</i>
968	54.	Genet 20 , 1162-1167 (2012).
969	55.	Fraser, H.B. & Plotkin, J.B. Using protein complexes to predict phenotypic effects of gene
970	55.	mutation. <i>Genome Biol</i> 8 , R252 (2007).
971	56.	Le, D.H. A novel method for identifying disease associated protein complexes based on
972	50.	functional similarity protein complex networks. <i>Algorithms Mol Biol</i> 10 , 14 (2015).
973	57.	Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of
974	071	anticancer drug sensitivity. <i>Nature</i> 483 , 603-607 (2012).
975	58.	Weinstein, J.N. Drug discovery: Cell lines battle cancer. <i>Nature</i> 483 , 544-545 (2012).
976	59.	Abaan, O.D. et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology
977		and systems pharmacology. <i>Cancer Res</i> 73 , 4372-4382 (2013).
978	60.	Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict
979		clinical trial drug response. Nat Med 21 , 1318-1325 (2015).
980	61.	Papillon-Cavanagh, S. et al. Comparison and validation of genomic predictors for anticancer
981		drug sensitivity. J Am Med Inform Assoc 20, 597-602 (2013).
982	62.	Jang, I.S., Neto, E.C., Guinney, J., Friend, S.H. & Margolin, A.A. Systematic assessment of
983		analytical methods for drug sensitivity prediction from cancer cell line data. Pacific
984		Symposium on Biocomputing. Pacific Symposium on Biocomputing, 63-74 (2014).
985	63.	Kosti, I., Jain, N., Aran, D., Butte, A.J. & Sirota, M. Cross-tissue Analysis of Gene and Protein
986		Expression in Normal and Cancer Tissues. Sci Rep 6, 24799 (2016).
987	64.	Schubert, O.T. et al. Building high-quality assay libraries for targeted analysis of SWATH MS
988		data. <i>Nat Protoc</i> 10 , 426-441 (2015).
989	65.	Craig, R. & Beavis, R.C. A method for reducing the time required to match protein sequences
990		with tandem mass spectra. Rapid Commun Mass Spectrom 17, 2310-2316 (2003).
991	66.	MacLean, B., Eng, J.K., Beavis, R.C. & McIntosh, M. General framework for developing and
992		evaluating database scoring algorithms using the TANDEM search engine. <i>Bioinformatics</i> 22,
993		2830-2832 (2006).
994	67.	Tabb, D.L., Fernando, C.G. & Chambers, M.C. MyriMatch: highly accurate tandem mass
995		spectral peptide identification by multivariate hypergeometric analysis. <i>J Proteome Res</i> 6,
996		654-661 (2007).
997	68.	Geer, L.Y. et al. Open mass spectrometry search algorithm. <i>J Proteome Res</i> 3 , 958-964 (2004).
998	69.	Eng, J.K., Jahan, T.A. & Hoopmann, M.R. Comet: an open-source MS/MS sequence database
999	70	search tool. <i>Proteomics</i> 13 , 22-24 (2013).
1000	70.	Keller, A., Nesvizhskii, A.I., Kolker, E. & Aebersold, R. Empirical statistical model to estimate
1001		the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74 ,
1002		5383-5392 (2002). 34

1003 1004 1005	71.	Shteynberg, D. et al. iProphet: multi-level integrative analysis of shotgun proteomic data improves peptide and protein identification rates and error estimates. <i>Molecular & cellular proteomics : MCP</i> 10 , M111 007690 (2011).
1006	72.	Keller, A., Eng, J., Zhang, N., Li, X.J. & Aebersold, R. A uniform proteomics MS/MS analysis
1007		platform utilizing open XML file formats. <i>Mol Syst Biol</i> 1 , 2005 0017 (2005).
1008	73.	Reiter, L. et al. Protein identification false discovery rates for very large proteomics data sets
1009		generated by tandem mass spectrometry. Molecular & cellular proteomics : MCP 8, 2405-
1010		2417 (2009).
1011	74.	Escher, C. et al. Using iRT, a normalized retention time for more targeted measurement of
1012		peptides. Proteomics 12 , 1111-1121 (2012).
1013	75.	Reiter, L. et al. Protein Identification False Discovery Rates for Very Large Proteomics Data
1014		Sets Generated by Tandem Mass Spectrometry. Molecular & Cellular Proteomics 8, 2405-
1015		2417 (2009).
1016	76.	Ruepp, A. et al. CORUM: the comprehensive resource of mammalian protein complexes
1017		2009. Nucleic Acids Res 38 , D497-501 (2010).
1018	77.	Vinayagam, A. et al. Protein complex-based analysis framework for high-throughput data
1019		sets. <i>Sci Signal</i> 6 , rs5 (2013).
1020	78.	Ori, A. et al. Cell type-specific nuclear pores: a case in point for context-dependent
1021		stoichiometry of molecular machines. <i>Mol Syst Biol</i> 9, 648 (2013).
1022	79.	Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via
1023		Coordinate Descent. J Stat Softw 33, 1-22 (2010).
1024	80.	Luna, A. et al. rcellminer: exploring molecular profiles and drug response of the NCI-60 cell
1025		lines in R. <i>Bioinformatics</i> 32 , 1272-1274 (2016).